As a high proportion of pancreatic tumours carry aberrations in G1/S checkpoint machinery, targeting PDAC subtypes that are dependent on CDK4/6 signalling may therefore be a reasonable therapeutic approach. This evidence concerns the gene CDK4 and pancreatic neoplasm.